Puma Biotechnology (PBYI) Projected to Post Quarterly Earnings on Thursday

Puma Biotechnology (NASDAQ:PBYI) is expected to announce its Q3 2025 results after the market closes on Thursday, November 6th. Analysts expect the company to announce earnings of $0.09 per share and revenue of $51.00 million for the quarter. Investors may review the information on the company’s upcoming Q3 2025 earningreport for the latest details on the call scheduled for Thursday, November 6, 2025 at 4:30 PM ET.

Puma Biotechnology Trading Down 1.2%

PBYI stock opened at $5.04 on Tuesday. Puma Biotechnology has a 1-year low of $2.32 and a 1-year high of $6.07. The company has a debt-to-equity ratio of 0.10, a current ratio of 1.73 and a quick ratio of 1.62. The company has a market capitalization of $253.87 million, a price-to-earnings ratio of 5.14 and a beta of 1.39. The business has a 50 day simple moving average of $5.01 and a two-hundred day simple moving average of $4.05.

Institutional Trading of Puma Biotechnology

Several hedge funds have recently modified their holdings of the company. Cerity Partners LLC purchased a new stake in Puma Biotechnology during the 2nd quarter valued at $36,000. Dynamic Technology Lab Private Ltd purchased a new stake in Puma Biotechnology during the 1st quarter valued at $66,000. Invesco Ltd. raised its holdings in Puma Biotechnology by 88.9% during the 1st quarter. Invesco Ltd. now owns 37,631 shares of the biopharmaceutical company’s stock valued at $111,000 after buying an additional 17,707 shares during the period. Jane Street Group LLC purchased a new stake in Puma Biotechnology during the 2nd quarter valued at $135,000. Finally, AQR Capital Management LLC raised its holdings in Puma Biotechnology by 366.5% during the 1st quarter. AQR Capital Management LLC now owns 50,458 shares of the biopharmaceutical company’s stock valued at $149,000 after buying an additional 39,641 shares during the period. 61.29% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have weighed in on PBYI shares. Wall Street Zen upgraded Puma Biotechnology from a “buy” rating to a “strong-buy” rating in a research note on Friday, September 5th. Weiss Ratings cut Puma Biotechnology from a “buy (b-)” rating to a “hold (c+)” rating in a report on Saturday, October 25th. One equities research analyst has rated the stock with a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $7.00.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.